File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes

TitleClenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes
Authors
Issue Date1995
Citation
Circulation, 1995, v. 92 n. 9 SUPPL., p. II483-II489 How to Cite?
AbstractBackground: Skeletal muscle assistance of the circulation for patients in end-stage heart failure requires electrical training of the latissimus dorsi flap to produce fatigue resistance. This process of electrical transformation and the development of postmobilization atrophy results in a profound loss in peak power generated. The β2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle. Methods and Results: Forty-one male Sprague- Dawley rats were divided into four groups and used in this study. Clenbuterol 2 μg · g body wt-1 · d-1 was administered subcutaneously for a period of either 5 weeks (group A) or 2 weeks (group A1). Groups B and B1 (controls) were injected with 0.5 mL normal saline once daily. At the end of the experimental period, all rats were weighed and terminally anesthetized for removal of the left LDM, left gastrocnemius-plantaris-soleus (GPS) muscles, and heart. The results showed that the increase in body weight did not differ significantly between the clenbuterol-treated and control groups (P>.5). The ratio of LDM to tibial length (hypertrophic index) for groups A and A1 was significantly greater than controls (P<.01), which represented a 20% to 29% increase. The hypertrophy was more pronounced for hindlimb skeletal muscle (21% to 35% for GPS), and the effects of this relatively high dose of clenbuterol on the heart were less marked (18% to 20% hypertrophy). RNA analyses indicate that ventricles of clenbuterol-treated rats express elevated levels of mRNA to atrial natriuretic factor without a concomitant increase in skeletal α-actin and β-myosin heavy chain, consistent with a 'physiological' form of cardiac hypertrophy. Conclusions: Clenbuterol induces significant hypertrophy of the LDM associated with specific changes in cardiac gene expression.
Persistent Identifierhttp://hdl.handle.net/10722/195235
ISSN
2015 Impact Factor: 17.047
2015 SCImago Journal Rankings: 7.853

 

DC FieldValueLanguage
dc.contributor.authorPetrou, M-
dc.contributor.authorWynne, DG-
dc.contributor.authorBoheler, KR-
dc.contributor.authorYacoub, MH-
dc.date.accessioned2014-02-25T01:40:20Z-
dc.date.available2014-02-25T01:40:20Z-
dc.date.issued1995-
dc.identifier.citationCirculation, 1995, v. 92 n. 9 SUPPL., p. II483-II489-
dc.identifier.issn0009-7322-
dc.identifier.urihttp://hdl.handle.net/10722/195235-
dc.description.abstractBackground: Skeletal muscle assistance of the circulation for patients in end-stage heart failure requires electrical training of the latissimus dorsi flap to produce fatigue resistance. This process of electrical transformation and the development of postmobilization atrophy results in a profound loss in peak power generated. The β2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle. Methods and Results: Forty-one male Sprague- Dawley rats were divided into four groups and used in this study. Clenbuterol 2 μg · g body wt-1 · d-1 was administered subcutaneously for a period of either 5 weeks (group A) or 2 weeks (group A1). Groups B and B1 (controls) were injected with 0.5 mL normal saline once daily. At the end of the experimental period, all rats were weighed and terminally anesthetized for removal of the left LDM, left gastrocnemius-plantaris-soleus (GPS) muscles, and heart. The results showed that the increase in body weight did not differ significantly between the clenbuterol-treated and control groups (P>.5). The ratio of LDM to tibial length (hypertrophic index) for groups A and A1 was significantly greater than controls (P<.01), which represented a 20% to 29% increase. The hypertrophy was more pronounced for hindlimb skeletal muscle (21% to 35% for GPS), and the effects of this relatively high dose of clenbuterol on the heart were less marked (18% to 20% hypertrophy). RNA analyses indicate that ventricles of clenbuterol-treated rats express elevated levels of mRNA to atrial natriuretic factor without a concomitant increase in skeletal α-actin and β-myosin heavy chain, consistent with a 'physiological' form of cardiac hypertrophy. Conclusions: Clenbuterol induces significant hypertrophy of the LDM associated with specific changes in cardiac gene expression.-
dc.languageeng-
dc.relation.ispartofCirculation-
dc.titleClenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid7586459-
dc.identifier.scopuseid_2-s2.0-0028862316-
dc.identifier.volume92-
dc.identifier.issue9 SUPPL.-
dc.identifier.spageII483-
dc.identifier.epageII489-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats